Brain pathology (Zurich, Switzerland)Oct 7, 2026

Muscle control differences in infant and adult Pompe patients revealed by combined molecular and structural analysis

Longevity & Aging Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 8, 2026

Abstract

A multi-omic analysis of skeletal muscle samples from 37 patients with Pompe disease revealed distinct regulatory patterns between late onset and infantile-onset forms.

Deregulated muscle processes were identified in late onset Pompe disease (LOPD) and infantile-onset Pompe disease (IOPD) samples, with differences in regulation at both transcript and protein levels.
Transcriptomic profiling indicated that immune processes were upregulated in both subtypes, while metabolic processes were primarily downregulated in LOPD.
A decrease in muscle development-related transcripts was specifically noted in IOPD samples.
Mass spectrometry analysis found reduced levels of sarcomeric proteins in LOPD, with alterations in chaperone-assisted selective autophagy observed in both subtypes.
Proteins involved in vesicle trafficking and biosynthesis showed a correlation with muscle pathology severity in LOPD.
Enzyme replacement therapy (ERT) in IOPD patients normalized many deregulated transcripts, although not entirely to baseline levels, and increased proteins associated with mitochondrial function and sarcomeric activity.

Simplified

Pompe disease is a lysosomal glycogen storage disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). There are two different clinical phenotypes, which are based on the age of onset, GAA variants, and residual enzyme activity. To better understand the regulation of age-dependent pathways in Pompe disease, we performed a multi-modal approach. We included mass spectrometry (MS) (liquid chromatography coupled to tandem mass spectrometry) and bulk-RNA sequencing on skeletal muscle samples from patients with late onset Pompe disease (LOPD) (n = 21) and infantile-onset Pompe disease (IOPD) (n = 11) naive to enzyme replacement therapy (ERT), IOPD patients with ERT (n = 5) and age-matched controls. The findings were verified by immunofluorescence studies and ultrastructural analysis using samples with different disease progression. We identified deregulated muscle processes in LOPD and IOPD samples, with different levels of regulation evident at the transcriptome and protein levels. Transcriptomic profiling revealed upregulation of immune processes in both Pompe subtypes, while metabolic processes were downregulated mainly in LOPD. Downregulation of transcripts associated with muscle development and myogenesis was only observed in IOPD samples. MS analysis revealed a decrease in the expression of sarcomeric proteins mainly in LOPD, while chaperone-assisted selective autophagy was altered in both Pompe subtypes. Proteins linked to vesicle trafficking and biosynthesis correlated with the degree of muscle pathology in LOPD, highlighting their role in the progression of the disease. IOPD patients treated with ERT showed normalised deregulated transcripts, though not fully back to baseline. Proteins increased with ERT were linked with mitochondrial and protein control pathways, and sarcomeric function, indicating ERT's positive effect on skeletal muscle function at the molecular level. Our findings reveal that combining a multi-omic approach, including morphological observations, enables the detection of a greater number of deregulated muscle processes, indicating both similar and distinct muscle processes in IOPD and LOPD.

Full Text

Full text is available at the source.

View Full Text ↗

Muscle control differences in infant and adult Pompe patients revealed by combined molecular and structural analysis

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief